In brain tumours, this finding is the first to report a p53-dependent anti-glioblastoma effect of a selective COX-2 inhibitor, which supports selective usage of celecoxib in human glioblastomas with functional p53 for enhanced anti-tumour responses. The gene discussed is TP53; the disease is glioblastoma.